CCL26–T2 Fusion Proteins for Dendritic Cell Antigen Presentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing tumor therapies lack effective methods to enhance antigen presentation by dendritic cells (DCs) for inducing robust CD8+ T cell immune responses, necessitating the identification of additional surface molecules to improve immune delivery systems.
Innovation Solution
A fusion protein comprising CCL26, an antigen, and a T2 fragment, specifically designed to enhance antigen delivery and presentation to DCs, utilizing the chemotactic properties of CCL26 to target immune cells expressing CX3CR1 or CCR3, thereby improving immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional tumor therapy methods are used, then treatment is provided, but effective enhancement of antigen presentation by dendritic cells is lacking
Solution Approach 1:
The patent introduces CCL26 as an intermediary molecule that mediates between the antigen and dendritic cells. CCL26 binds to CX3CR1 receptors on dendritic cell surface, serving as a bridge to enhance antigen delivery and presentation, thereby resolving the contradiction between reliable antigen presentation and efficient immune response induction
Solution Approach 2:
The invention creates a composite structure by fusing CCL26 with the antigen of interest. This composite fusion protein combines the antigen-presenting function with the chemotactic and cell-targeting properties of CCL26, enabling both reliable antigen presentation and enhanced immune response induction simultaneously
2Productivity
If tumor antigens are delivered to DCs using conventional methods, then antigen delivery occurs, but robust CD8+ T cell immune responses are not induced
Solution Approach 1:
The patent merges multiple functions into a single fusion protein molecule: the antigen sequence, the CCL26 chemokine sequence, and linkers. This unified structure combines antigen presentation capability with active targeting to dendritic cells, achieving robust CD8+ T cell responses without requiring complex multi-component delivery systems
3Productivity
If CCL26/antigen fusion molecule is used, then antigen uptake by DCs is promoted, but system complexity increases
Solution Approach 1:
The patent optimizes specific parameters of the fusion protein including the linker length and sequence (e.g., (G4S)3 or (G5S)4), the stoichiometry of CCL26 to antigen, and the orientation of fusion. These parameter optimizations enhance antigen uptake efficiency by DCs while managing the structural complexity through systematic design rather than random complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The fusion protein effectively enhances antigen presentation and immune responses, increasing the number of specific T cells and humoral immune responses, providing a potent vaccine preparation for preventing and treating diseases, including tumors.
Implementation Method 1
CCL26 is a small cytokine typical of the CC subfamily... highly expressed in vascular endothelial cells stimulated by IL-4 and IL-13, thereby promoting the chemotaxis of immune cells expressing its receptors
Data Source
AI summary
A use of CCL26. Different antigen proteins are delivered to the surfaces of DC cells by utilizing a chemotactic binding capacity of CCL26 to surface receptors of immune cells such as the DC cells, so that the efficiency of phagocytosis, processing and presentation of different antigen proteins by the DC cells is improved, and the effect of preventing and treating related diseases is improved by further adding a T2 sequence into an antigen. The T2 sequence has a very strong immunological enhancement effect by means of experimental determination, and can further excite body fluid and cellular immune response in the process of promoting antigen presentation, thereby finally achieving the effect of inhibiting related tumor growth.